CDC Clinical Considerations Issued for Updated 2023–2024 Formulation of Novavax COVID-19 Vaccine
This email is being sent to local health officers, Tribal health directors, COVID-19 vaccinators, COVID-19 vaccine stakeholders, HERC coordinators, VFC providers, and key DHS staff.
On October 6, the Centers for Disease Control and Prevention (CDC) issued updated clinical considerations to inform the administration of the updated 2023–2024 formulation of the Novavax COVID-19 vaccine.
The Immunization Program's Policy and Procedure (P&P) Manual is expected to be updated later this week. A reminder that local health departments (LHDs) cannot administer the updated 2023–2024 formulation of the Novavax COVID-19 vaccine to the individuals detailed in the CDC clinical considerations until the Immunization Program’s P&P Manual is updated. All other vaccinators can vaccinate in accordance with the updated clinical guidance from the CDC.
Summary of recent changes to CDC clinical considerations
Below is a summary only and vaccinators should read the full update to the CDC clinical considerations for specific recommendations.
-
The updated 2023–2024 formulation of the Novavax COVID-19 vaccine is recommended for people ages 12 years and older as follows:
- Initial vaccination: 2 doses of updated (2023–2024 formula) Novavax COVID-19 vaccine.
-
Previously vaccinated with any original monovalent or bivalent COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech, Janssen): 1 dose of updated (2023–2024 Formula) Novavax vaccine.
-
People who are moderately or severely immunocompromised may receive 1 or more additional updated (2023–2024 formula) Novavax vaccine doses.
-
People ages 12 years and older have the option of receiving either the updated (2023–2024 formula) mRNA (Moderna or Pfizer-BioNTech) or the updated (2023–2024 formula) Novavax vaccine.
Original monovalent Novavax vaccine no longer authorized for use
The Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent) is no longer authorized for use in the United States.
FDA 2023–2024 authorized Novavax COVID-19 vaccine information page
For more details regarding the disposal of the original monovalent Novavax and the storage and handling of the updated 2023–2024 formulation of the Novavax COVID-19 vaccine, read the bulletin sent on Friday, October 6.
|
